{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:45:09Z","timestamp":1790775909448,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_155957"],"award-info":[{"award-number":["32003B_155957"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertonic lactate (HL) is emerging as alternative treatment of intracranial hypertension following acute brain injury (ABI), but comparative studies are limited. Here, we examined the effectiveness of HL on main cerebral and systemic physiologic variables, and further compared it to that of standard hypertonic saline (HS). Retrospective cohort analysis of ABI subjects who received sequential osmotherapy with 7.5% HS followed by HL\u2014given at equi-osmolar (2400\u00a0mOsmol\/L) and isovolumic (1.5\u00a0mL\/kg) bolus doses\u2014to reduce sustained elevations of ICP (&gt;\u200920\u00a0mmHg). The effect of HL on brain (intracranial pressure [ICP], brain tissue PO<jats:sub>2<\/jats:sub> [PbtO<jats:sub>2<\/jats:sub>], cerebral microdialysis [CMD] glucose and lactate\/pyruvate ratio [LPR]) and blood (chloride, pH) variables was examined at different time-points (30, 60, 90, 120\u00a0min vs. baseline), and compared to that of HS. A total of 34 treatments among 17 consecutive subjects (13 traumatic brain injury [TBI], 4 non-TBI) were studied. Both agents significantly reduced ICP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, at all time-points tested): when comparing treatment effectiveness, absolute ICP decrease in mmHg and the duration of treatment effect (median time with ICP\u2009&lt;\u200920\u00a0mmHg following osmotherapy 183 [108\u2013257] vs. 150 [111\u2013419] min) did not differ significantly between HL and HS (all <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.2). None of the treatment had statistically significant effects on PbtO<jats:sub>2<\/jats:sub> and CMD biomarkers. Treatment with HL did not cause hyperchloremia and resulted in a more favourable systemic chloride balance than HS (\u0394 blood chloride \u2212\u20091\u2009\u00b1\u20092.5 vs. +\u20094\u2009\u00b1\u20093\u00a0mmol\/L; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). This is the first clinical study showing that HL has comparative effectiveness than HS for the treatment of intracranial hypertension, while at the same time avoiding hyperchloremic acidosis. Both agents had no significant effect on cerebral oxygenation and metabolism.<\/jats:p>","DOI":"10.1038\/s41598-022-07129-z","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T11:02:51Z","timestamp":1645527771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hypertonic lactate for the treatment of intracranial hypertension in patients with acute brain injury"],"prefix":"10.1038","volume":"12","author":[{"given":"Adriano","family":"Bernini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Miroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Abed-Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Iaquaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawfel","family":"Ben-Hamouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Oddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"7129_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MCC.0000000000000072","volume":"20","author":"P Bouzat","year":"2014","unstructured":"Bouzat, P. & Oddo, M. Lactate and the injured brain: Friend or foe?. Curr. Opin. Crit. Care 20, 133\u2013140. https:\/\/doi.org\/10.1097\/MCC.0000000000000072 (2014).","journal-title":"Curr. Opin. Crit. Care"},{"key":"7129_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrn.2018.19","volume":"19","author":"PJ Magistretti","year":"2018","unstructured":"Magistretti, P. J. & Allaman, I. Lactate in the brain: From metabolic end-product to signalling molecule. Nat. Rev. Neurosci. 19, 235\u2013249. https:\/\/doi.org\/10.1038\/nrn.2018.19 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"7129_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00134-013-3203-6","volume":"40","author":"P Bouzat","year":"2014","unstructured":"Bouzat, P. et al. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med 40, 412\u2013421. https:\/\/doi.org\/10.1007\/s00134-013-3203-6 (2014).","journal-title":"Intensive Care Med"},{"key":"7129_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/neu.2015.4057","volume":"33","author":"H Quintard","year":"2016","unstructured":"Quintard, H. et al. Improvement of neuroenergetics by hypertonic lactate therapy in patients with traumatic brain injury is dependent on baseline cerebral lactate\/pyruvate ratio. J. Neurotrauma 33, 681\u2013687. https:\/\/doi.org\/10.1089\/neu.2015.4057 (2016).","journal-title":"J. Neurotrauma"},{"key":"7129_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/CCM.0000000000003274","volume":"46","author":"L Carteron","year":"2018","unstructured":"Carteron, L. et al. Hypertonic lactate to improve cerebral perfusion and glucose availability after acute brain injury. Crit. Care Med. 46, 1649\u20131655. https:\/\/doi.org\/10.1097\/CCM.0000000000003274 (2018).","journal-title":"Crit. Care Med."},{"key":"7129_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00134-008-1283-5","volume":"35","author":"C Ichai","year":"2009","unstructured":"Ichai, C. et al. Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med. 35, 471\u2013479. https:\/\/doi.org\/10.1007\/s00134-008-1283-5 (2009).","journal-title":"Intensive Care Med."},{"key":"7129_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00134-018-5086-z","volume":"44","author":"M Oddo","year":"2018","unstructured":"Oddo, M. et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. Intensive Care Med. 44, 449\u2013463. https:\/\/doi.org\/10.1007\/s00134-018-5086-z (2018).","journal-title":"Intensive Care Med."},{"key":"7129_CR8","doi-asserted-by":"publisher","first-page":"R260","DOI":"10.1186\/cc10522","volume":"15","author":"A Roquilly","year":"2011","unstructured":"Roquilly, A. et al. Continuous controlled-infusion of hypertonic saline solution in traumatic brain-injured patients: A 9-year retrospective study. Crit. Care 15, R260. https:\/\/doi.org\/10.1186\/cc10522 (2011).","journal-title":"Crit. Care"},{"key":"7129_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1227\/NEU.0000000000001432","volume":"80","author":"N Carney","year":"2017","unstructured":"Carney, N. et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 80, 6\u201315. https:\/\/doi.org\/10.1227\/NEU.0000000000001432 (2017).","journal-title":"Neurosurgery"},{"key":"7129_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/CCM.0b013e318206b9be","volume":"39","author":"H Kamel","year":"2011","unstructured":"Kamel, H., Navi, B. B., Nakagawa, K., Hemphill, J. C. 3rd. & Ko, N. U. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: A meta-analysis of randomized clinical trials. Crit. Care Med. 39, 554\u2013559. https:\/\/doi.org\/10.1097\/CCM.0b013e318206b9be (2011).","journal-title":"Crit. Care Med."},{"key":"7129_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1089\/neu.2011.1929","volume":"28","author":"V Cottenceau","year":"2011","unstructured":"Cottenceau, V. et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. J. Neurotrauma 28, 2003\u20132012. https:\/\/doi.org\/10.1089\/neu.2011.1929 (2011).","journal-title":"J. Neurotrauma"},{"key":"7129_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyz046","author":"HS Mangat","year":"2019","unstructured":"Mangat, H. S. et al. Hypertonic saline is superior to mannitol for the combined effect on intracranial pressure and cerebral perfusion pressure burdens in patients with severe traumatic brain injury. Neurosurgery https:\/\/doi.org\/10.1093\/neuros\/nyz046 (2019).","journal-title":"Neurosurgery"},{"key":"7129_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/jnnp.2008.156596","volume":"80","author":"M Oddo","year":"2009","unstructured":"Oddo, M. et al. Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension. J. Neurol. Neurosurg. Psychiatry 80, 916\u2013920. https:\/\/doi.org\/10.1136\/jnnp.2008.156596 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"7129_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/STROKEAHA.109.560698","volume":"41","author":"PG Al-Rawi","year":"2010","unstructured":"Al-Rawi, P. G. et al. Hypertonic saline in patients with poor-grade subarachnoid hemorrhage improves cerebral blood flow, brain tissue oxygen, and pH. Stroke 41, 122\u2013128. https:\/\/doi.org\/10.1161\/STROKEAHA.109.560698 (2010).","journal-title":"Stroke"},{"key":"7129_CR15","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2019.6399","author":"JR Anstey","year":"2019","unstructured":"Anstey, J. R. et al. Early osmotherapy in severe traumatic brain injury: An international multicenter study. J. Neurotrauma. https:\/\/doi.org\/10.1089\/neu.2019.6399 (2019).","journal-title":"J. Neurotrauma."},{"key":"7129_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/MCC.0000000000000114","volume":"20","author":"D Gantner","year":"2014","unstructured":"Gantner, D., Moore, E. M. & Cooper, D. J. Intravenous fluids in traumatic brain injury: What\u2019s the solution?. Curr. Opin. Crit. Care 20, 385\u2013389. https:\/\/doi.org\/10.1097\/MCC.0000000000000114 (2014).","journal-title":"Curr. Opin. Crit. Care"},{"key":"7129_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nature07525","volume":"456","author":"GR Gordon","year":"2008","unstructured":"Gordon, G. R., Choi, H. B., Rungta, R. L., Ellis-Davies, G. C. & MacVicar, B. A. Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456, 745\u2013749. https:\/\/doi.org\/10.1038\/nature07525 (2008).","journal-title":"Nature"},{"key":"7129_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.jcbfm.9600073","volume":"25","author":"P Vespa","year":"2005","unstructured":"Vespa, P. et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: A combined microdialysis and positron emission tomography study. J. Cereb. Blood Flow Metab. 25, 763\u2013774. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600073 (2005).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"7129_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1097\/01.CCM.0000259466.66310.4F","volume":"35","author":"PM Vespa","year":"2007","unstructured":"Vespa, P. M. et al. Pericontusional brain tissue exhibits persistent elevation of lactate\/pyruvate ratio independent of cerebral perfusion pressure. Crit. Care Med. 35, 1153\u20131160. https:\/\/doi.org\/10.1097\/01.CCM.0000259466.66310.4F (2007).","journal-title":"Crit. Care Med."},{"key":"7129_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12028-010-9342-5","volume":"12","author":"R Lakshmanan","year":"2010","unstructured":"Lakshmanan, R. et al. Metabolic crisis after traumatic brain injury is associated with a novel microdialysis proteome. Neurocrit. Care 12, 324\u2013336. https:\/\/doi.org\/10.1007\/s12028-010-9342-5 (2010).","journal-title":"Neurocrit. Care"},{"key":"7129_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/0897715041526195","volume":"21","author":"R Hlatky","year":"2004","unstructured":"Hlatky, R., Valadka, A. B., Goodman, J. C., Contant, C. F. & Robertson, C. S. Patterns of energy substrates during ischemia measured in the brain by microdialysis. J. Neurotrauma 21, 894\u2013906. https:\/\/doi.org\/10.1089\/0897715041526195 (2004).","journal-title":"J. Neurotrauma"},{"key":"7129_CR22","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1177\/0271678X16666552","volume":"36","author":"GA Dienel","year":"2016","unstructured":"Dienel, G. A., Rothman, D. L. & Nordstrom, C. H. Microdialysate concentration changes do not provide sufficient information to evaluate metabolic effects of lactate supplementation in brain-injured patients. J. Cereb. Blood Flow Metab. 36, 1844\u20131864. https:\/\/doi.org\/10.1177\/0271678X16666552 (2016).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"7129_CR23","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1097\/CCM.0000000000002522","volume":"45","author":"HM Riha","year":"2017","unstructured":"Riha, H. M. et al. Impact of moderate hyperchloremia on clinical outcomes in intracerebral hemorrhage patients treated with continuous infusion hypertonic saline: A pilot study. Crit. Care Med. 45, e947\u2013e953. https:\/\/doi.org\/10.1097\/CCM.0000000000002522 (2017).","journal-title":"Crit. Care Med."},{"key":"7129_CR24","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/CCM.0000000000002497","volume":"45","author":"O Sadan","year":"2017","unstructured":"Sadan, O., Singbartl, K., Kandiah, P. A., Martin, K. S. & Samuels, O. B. Hyperchloremia is associated with acute kidney injury in patients with subarachnoid hemorrhage. Crit. Care Med. 45, 1382\u20131388. https:\/\/doi.org\/10.1097\/CCM.0000000000002497 (2017).","journal-title":"Crit. Care Med."},{"key":"7129_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1711584","volume":"378","author":"MW Semler","year":"2018","unstructured":"Semler, M. W. et al. Balanced crystalloids versus saline in critically ill adults. N. Engl. J. Med. 378, 829\u2013839. https:\/\/doi.org\/10.1056\/NEJMoa1711584 (2018).","journal-title":"N. Engl. J. Med."},{"key":"7129_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/CCM.0B013E3181643B41","volume":"36","author":"G Francony","year":"2008","unstructured":"Francony, G. et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Crit. Care Med. 36, 795\u2013800. https:\/\/doi.org\/10.1097\/CCM.0B013E3181643B41 (2008).","journal-title":"Crit. Care Med."},{"key":"7129_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.ccm.0000150269.65485.a6","volume":"33","author":"C Battison","year":"2005","unstructured":"Battison, C., Andrews, P. J., Graham, C. & Petty, T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline\/6% dextran solution on increased intracranial pressure after brain injury. Crit. Care Med. 33, 196\u2013202. https:\/\/doi.org\/10.1097\/01.ccm.0000150269.65485.a6 (2005) (discussion 257\u2013198).","journal-title":"Crit. Care Med."},{"key":"7129_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1097\/01.CCM.0000063268.91710.DF","volume":"31","author":"R Vialet","year":"2003","unstructured":"Vialet, R. et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2\u00a0mL\/kg 7.5% saline is more effective than 2\u00a0mL\/kg 20% mannitol. Crit. Care Med. 31, 1683\u20131687. https:\/\/doi.org\/10.1097\/01.CCM.0000063268.91710.DF (2003).","journal-title":"Crit. Care Med."},{"key":"7129_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12028-011-9605-9","volume":"15","author":"MN Diringer","year":"2011","unstructured":"Diringer, M. N. et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: Recommendations from the Neurocritical Care Society\u2019s Multidisciplinary Consensus Conference. Neurocrit. Care 15, 211\u2013240. https:\/\/doi.org\/10.1007\/s12028-011-9605-9 (2011).","journal-title":"Neurocrit. Care"},{"key":"7129_CR30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly Jr","year":"2012","unstructured":"Connolly, E. S. Jr. et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 43, 1711\u20131737. https:\/\/doi.org\/10.1161\/STR.0b013e3182587839 (2012).","journal-title":"Stroke"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07129-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:21:43Z","timestamp":1669332103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07129-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7129"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07129-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3035"}}